Royal Bank Of Canada Boosts Intellia Therapeutics (NASDAQ:NTLA) Price Target to $15.00

Intellia Therapeutics (NASDAQ:NTLA) had its target price raised by equities researchers at Royal Bank Of Canada from $9.00 to $15.00 in a research report issued on Tuesday,Benzinga reports. The brokerage currently has a “sector perform” rating on the stock. Royal Bank Of Canada’s price objective indicates a potential upside of 8.54% from the stock’s previous close.

Several other equities research analysts have also recently issued reports on the stock. Oppenheimer set a $27.00 target price on shares of Intellia Therapeutics in a research note on Friday, November 7th. William Blair upgraded shares of Intellia Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Monday. Chardan Capital reaffirmed a “buy” rating and set a $26.00 price objective on shares of Intellia Therapeutics in a research note on Friday, February 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Intellia Therapeutics in a research note on Thursday, January 22nd. Finally, HC Wainwright upped their price target on Intellia Therapeutics from $25.00 to $30.00 and gave the company a “buy” rating in a research report on Tuesday. Eleven equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $19.59.

Intellia Therapeutics Price Performance

Shares of Intellia Therapeutics stock opened at $13.82 on Tuesday. The business has a 50 day simple moving average of $12.17 and a two-hundred day simple moving average of $13.10. Intellia Therapeutics has a 12 month low of $5.90 and a 12 month high of $28.25. The stock has a market capitalization of $1.63 billion, a P/E ratio of -3.61 and a beta of 2.10.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.99) by $0.16. Intellia Therapeutics had a negative return on equity of 56.81% and a negative net margin of 609.85%.The firm had revenue of $23.02 million for the quarter, compared to analyst estimates of $12.17 million. During the same period in the previous year, the company posted ($1.27) earnings per share. The business’s revenue was up 78.4% on a year-over-year basis. As a group, research analysts anticipate that Intellia Therapeutics will post -5.07 EPS for the current fiscal year.

Insider Buying and Selling

In other Intellia Therapeutics news, CEO John M. Leonard sold 34,146 shares of the firm’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $9.21, for a total transaction of $314,484.66. Following the completion of the sale, the chief executive officer owned 1,013,339 shares of the company’s stock, valued at $9,332,852.19. This trade represents a 3.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP James Basta sold 10,397 shares of the company’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $9.21, for a total value of $95,756.37. Following the completion of the transaction, the executive vice president directly owned 101,528 shares in the company, valued at approximately $935,072.88. This trade represents a 9.29% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 53,051 shares of company stock worth $488,600. Company insiders own 3.10% of the company’s stock.

Institutional Investors Weigh In On Intellia Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Virtu Financial LLC purchased a new position in Intellia Therapeutics in the 4th quarter valued at approximately $245,000. Invesco Ltd. raised its stake in shares of Intellia Therapeutics by 5.8% in the fourth quarter. Invesco Ltd. now owns 433,290 shares of the company’s stock valued at $3,895,000 after acquiring an additional 23,870 shares in the last quarter. Axxcess Wealth Management LLC boosted its holdings in Intellia Therapeutics by 20.1% in the fourth quarter. Axxcess Wealth Management LLC now owns 21,399 shares of the company’s stock valued at $192,000 after purchasing an additional 3,583 shares during the period. Mercer Global Advisors Inc. ADV acquired a new position in Intellia Therapeutics during the 4th quarter worth $90,000. Finally, XTX Topco Ltd acquired a new position in Intellia Therapeutics during the 4th quarter worth $402,000. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Intellia Therapeutics

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: FDA lifts clinical holds / allows second in‑human trial to resume, removing a major regulatory overhang and clearing Intellia to restart an important gene‑editing program. Read More. Read More.
• Positive Sentiment: Multiple analyst upgrades and target increases (JonesTrading to Buy, Leerink & HC Wainwright bumping targets, William Blair upgrade to Outperform) have supported sentiment and likely drove buying interest. JonesTrading set a $29 PT; HC Wainwright raised its PT to $30. Read More. Read More.
• Positive Sentiment: Intellia presented longer‑term clinical data for lonvoguran (lonvo‑z) at AAAAI showing multi‑year follow‑up after a one‑time dose — reinforces the durability narrative for a key therapeutic candidate. Read More.
• Positive Sentiment: High‑profile investor interest: Cathie Wood’s Ark (coverage piece) noted buying activity in beaten‑up growth names, including Intellia — a potential source of additional demand from momentum/growth investors. Read More.
• Neutral Sentiment: Other broker moves mixed: RBC, Wells Fargo and others nudged targets modestly higher (to ~$15), while Canaccord cut its target from $54 to $48 — consensus remains wide, reflecting varying views on timelines and commercialization risk. Read More.
• Negative Sentiment: HC Wainwright trimmed near‑term EPS estimates across several 2026 quarters and lowered full‑year forecasts slightly even while maintaining a Buy and a $30 PT — a reminder analysts expect continued cash burn and negative earnings into 2026. This raises execution risk and could limit multiple expansion. Read More.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.